ArticleOncology reports2020
Mechanistic investigations of antitumor activity of a Rhodamine B‑oleanolic acid derivative bioconjugate.
Article in Oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Oleanolic acid-chitosan compound inhibits mitochondrial autophagy and malignant transformation of lung cancer through the PTEN/AKT pathway.Turkish journal of medical sciences · 2026Article
- Mitochondria-targeted strategies in tumor immunity.Frontiers in immunology · 2025Review
- Antioxidant Extracts from Greek and Spanish Olive Leaves: Antimicrobial, Anticancer and Antiangiogenic Effects.Antioxidants (Basel, Switzerland) · 2024Article
- Progress in Antimelanoma Research of Natural Triterpenoids and Their Derivatives: Mechanisms of Action, Bioavailability Enhancement and Structure Modifications.Molecules (Basel, Switzerland) · 2023Review
- The Finally Rewarding Search for A Cytotoxic Isosteviol Derivative.Molecules (Basel, Switzerland) · 2023Article
- Anti-cancer potential of substituted "amino-alkyl-rhodamine" derivatives against MCF-7 human breast cancer cell line.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- In Vitro and In Ovo Evaluation of the Potential Hepatoprotective Effect of Metformin.Medicina (Kaunas, Lithuania) · 2022Article
- Iron oxide nanoflowers encapsulated in thermosensitive fluorescent liposomes for hyperthermia treatment of lung adenocarcinoma.Scientific reports · 2022Article
- Methotrexate and Cetuximab-Biological Impact on Non-Tumorigenic Models: In Vitro and In Ovo Assessments.Medicina (Kaunas, Lithuania) · 2022Article
- Impact of COVID-19 prevention measures onExperimental and therapeutic medicine · 2021Article
- Anti-Cancer Potential of Synthetic Oleanolic Acid Derivatives and Their Conjugates with NSAIDs.Molecules (Basel, Switzerland) · 2021Review
- Recent Progress in Small Spirocyclic, Xanthene-Based Fluorescent Probes.Molecules (Basel, Switzerland) · 2020Review
- High Concentrations of Aspartame Induce Pro-Angiogenic Effects in Ovo and Cytotoxic Effects in HT-29 Human Colorectal Carcinoma Cells.Nutrients · 2020Article
- In vitro and in ovo experimental study of two anti-VEGF agents used in ophthalmology.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a major health problem worldwide due to its high mortality rate. New therapeutic options highlight the importance of discovering new compounds that target the tumor microenvironment, interrupt angiogenesis and act selectively. The present study assessed the antitumor effect and investigated the mechanism of action of a rhodamine B‑conjugated oleanolic acid derivative (RhodOA). Consequently, the compound was tested on different human tumor cell lines (A375 melanoma, A549 lung adenocarcinoma and MDA‑MB‑231 breast adenocarcinoma) and on a non‑tumor cell line HaCaT human keratinocyte. RhodOA produced a dose‑dependent decrease in tumor cell viability especially in the melanoma cells while affecting the keratinocytes less. In melanoma cells, RhodOA reduced cell migration and produced condensation of cell nuclei and of actin fibers. Furthermore, an impairment in melanoma cell mitochondrial function was observed, while the mitochondrial function of keratinocytes was left intact. In the in ovo chorioallantoic membrane model, RhodOA elicited antiangiogenic effect, without showing irritation effect on the membrane. The study provides information on the selective antitumor effect of the derivative and its ability to inhibit cellular respiration, therefore RhodOA can be classified as 'MITOCAN'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.